The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kumar, D., Luan, L., Pathak, S., Salhan, D., Magoon, S., & Singhal, P. C. (2010) · Renal Failure · doi:10.3109/0886022x.2010.501936 · Cited by 6
RetractedInternational Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
SOME QUANTITATIVE USES OF DRUG ANTAGONISTS
ARUNLAKSHANA, O., & SCHILD, H. O. (1959) · British Journal of Pharmacology and Chemotherapy · doi:10.1111/j.1476-5381.1959.tb00928.x · Cited by 3,938
Uric Acid and Cardiovascular Risk
Feig, D. I., Kang, D.-H., & Johnson, R. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0800885 · Cited by 2,440
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W. (2004) · Hypertension · doi:10.1161/01.hyp.0000123072.34629.57 · Cited by 1,073
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation
Klaassen, C. D., & Aleksunes, L. M. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002014 · Cited by 807
H1-Receptor Antagonists: Comparative Tolerability and Safety
Estelle, F., & Simons, R. (1994) · Drug Safety · doi:10.2165/00002018-199410050-00002 · Cited by 751
Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity
Schupp, M., Janke, J., Clasen, R., Unger, T., & Kintscher, U. (2004) · Circulation · doi:10.1161/01.cir.0000127955.36250.65 · Cited by 705
Singh, K. D., & Karnik, S. S. (2020) · GPCRs · doi:10.1016/b978-0-12-816228-6.00020-9 · Cited by 704
Neubig, R. R., Spedding, M., Kenakin, T., & Christopoulos, A. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.4 · Cited by 665
Leesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 566
Angiotensin II Type 1 Receptor Blockers
Burnier, M. (2001) · Circulation · doi:10.1161/01.cir.103.6.904 · Cited by 485
Yazdanian, M., Glynn, S. L., Wright, J. L., & Hawi, A. (1998) · Pharmaceutical Research · doi:10.1023/a:1011930411574 · Cited by 453
Violin, J. D., DeWire, S. M., Yamashita, D., Rominger, D. H., Nguyen, L., Schiller, K., Whalen, E. J., Gowen, M., & Lark, M. W. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173005 · Cited by 370
Anzai, N., Ichida, K., Jutabha, P., Kimura, T., Babu, E., Jin, C. J., Srivastava, S., Kitamura, K., Hisatome, I., Endou, H., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800156200 · Cited by 359
Tsuchida, S., Matsusaka, T., Chen, X., Okubo, S., Niimura, F., Nishimura, H., Fogo, A., Utsunomiya, H., Inagami, T., & Ichikawa, I. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1899 · Cited by 335
Role of the Intrarenal Renin-Angiotensin-Aldosterone System in Chronic Kidney Disease
Siragy, H. M., & Carey, R. M. (2010) · American Journal of Nephrology · doi:10.1159/000313363 · Cited by 293
Kohara, Y., Kubo, K., Imamiya, E., Wada, T., Inada, Y., & Naka, T. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm960547h · Cited by 275
Schupp, M., Clemenz, M., Gineste, R., Witt, H., Janke, J., Helleboid, S., Hennuyer, N., Ruiz, P., Unger, T., Staels, B., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3442 · Cited by 274
Wong, P. C., Price, W. A., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L., & Timmermans, P. B. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)19984-9 · Cited by 269
A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor Antagonist
Wienen, W., Entzeroth, M., van Meel, J. C. A., Stangier, J., Busch, U., Ebner, T., Schmid, J., Lehmann, H., Matzek, K., Kempthorne‐Rawson, J., et al. (2000) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2000.tb00039.x · Cited by 258
PPARγ-Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin
Clasen, R., Schupp, M., Foryst-Ludwig, A., Sprang, C., Clemenz, M., Krikov, M., Thöne-Reineke, C., Unger, T., & Kintscher, U. (2005) · Hypertension · doi:10.1161/01.hyp.0000168046.19884.6a · Cited by 257
Criscione, L., de Gasparo, M., Bühlmayer, P., Whitebread, S., Ramjoué, H. R., & Wood, J. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13877.x · Cited by 250
The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
Fromm, M. F. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00064-9 · Cited by 247
Christen, Y., Waeber, B., Nussberger, J., Porchet, M., Borland, R. M., Lee, R. J., Maggon, K., Shum, L., Timmermans, P. B., & Brunner, H. R. (1991) · Circulation · doi:10.1161/01.cir.83.4.1333 · Cited by 244
Self-citationBrain renin-angiotensin—A new look at an old system
Wright, J. W., & Harding, J. W. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.07.001 · Cited by 233
Pharmacological analysis of drug-receptor interaction
Kietzmann, M. (1994) · Toxicon · doi:10.1016/0041-0101(94)90098-1 · Cited by 224
Local adipose tissue renin-angiotensin system
Cassis, L. A., Police, S. B., Yiannikouris, F., & Thatcher, S. E. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0019-9 · Cited by 223
Regulation of Uric Acid Excretion by the Kidney
Lipkowitz, M. S. (2012) · Current Rheumatology Reports · doi:10.1007/s11926-012-0240-z · Cited by 221
Shibouta, Y., Inada, Y., Ojima, M., Wada, T., Noda, M., Sanada, T., Kubo, K., Kohara, Y., Naka, T., & Nishikawa, K. (1993) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38306-0 · Cited by 213
Efficacy as a Vector: the Relative Prevalence and Paucity of Inverse Agonism
Kenakin, T. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.2 · Cited by 213
Stangier, J., Su, C., & Roth, W. (2000) · Journal of International Medical Research · doi:10.1177/147323000002800401 · Cited by 210
Stearns, R. A., Chakravarty, P. K., Chen, R., & Chiu, S. H. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06520-1 · Cited by 208
Ries, U. J., Mihm, G., Narr, B., Hasselbach, K. M., Wittneben, H., Entzeroth, M., van Meel, J. C. A., Wienen, W., & Hauel, N. H. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00077a007 · Cited by 204
Flesch, G., Müller, P., & Lloyd, P. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050259 · Cited by 203
Yamashiro, W., Maeda, K., Hirouchi, M., Adachi, Y., Hu, Z., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008938 · Cited by 202
MAEDA, K., IEIRI, I., YASUDA, K., FUJINO, A., FUJIWARA, H., OTSUBO, K., HIRANO, M., WATANABE, T., KITAMURA, Y., & KUSUHARA, H. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.01.011 · Cited by 200
Champion, H. C., Bivalacqua, T. J., Lambert, D. G., McNamara, D. B., & Kadowitz, P. J. (1999) · PubMed · Cited by 199
Grapefruit Juice Activates P-Glycoprotein-Mediated Drug Transport
Soldner, A., Christians, U., Susanto, M., Wacher, V. J., Silverman, J. A., & Benet, L. Z. (1999) · Pharmaceutical Research · doi:10.1023/a:1011902625609 · Cited by 193
Tsukuda, K., Mogi, M., Iwanami, J., Min, L.-J., Sakata, A., Jing, F., Iwai, M., & Horiuchi, M. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.136879 · Cited by 191
Wienen, W., Hauel, N., Van Meel, J. C. A., Narr, B., Ries, U., & Entzeroth, M. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13800.x · Cited by 191
Speth, R. C., & Kim, K. H. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)91993-3 · Cited by 190
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification.
Vanhoutte, P. M., Barnard, E. A., Cosmides, G. J., Humphrey, P. P., Spedding, M., & Godfraind, T. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06779-1 · Cited by 188
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Yasar, Ü., Forslund‐Bergengren, C., Tybring, G., Dorado, P., LLerena, A., Sjöqvist, F., Eliasson, E., & Dahl, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121216 · Cited by 183
Kurtz, T. W., & Pravenec, M. (2004) · Journal of Hypertension · doi:10.1097/00004872-200412000-00003 · Cited by 182
Progress in Brain Penetration Evaluation in Drug Discovery and Development
Liu, X., Chen, C., & Smith, B. J. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130294 · Cited by 182
Fleegal-DeMotta, M. A., Doghu, S., & Banks, W. A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.158 · Cited by 180
Ishiguro, N., Maeda, K., Kishimoto, W., Saito, A., Harada, A., Ebner, T., Roth, W., Igarashi, T., & Sugiyama, Y. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.009175 · Cited by 178
Wong, P. C., Price, W. A., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L., & Timmermans, P. B. (1990) · Hypertension · doi:10.1161/01.hyp.15.5.459 · Cited by 175
Oliverio, M. I., Best, C. F., Kim, H. S., Arendshorst, W. J., Smithies, O., & Coffman, T. M. (1997) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1997.272.4.f515 · Cited by 166
Jenkinson, D. H., Barnard, E. A., Hoyer, D., Humphrey, P. P., Leff, P., & Shankley, N. P. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06844-9 · Cited by 161
The Docking of Arg2 of Angiotensin II with Asp281 of AT1 Receptor Is Essential for Full Agonism
Feng, Y.-H., Noda, K., Saad, Y., Liu, X.-P., Husain, A., & Karnik, S. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12846 · Cited by 160
Laeis, P., Püchler, K., & Kirch, W. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106001-00004 · Cited by 156
Angiotensin-II-binding sites on hepatocyte nuclei
Booz, G. W., Conrad, K., Hess, A., Singer, H. A., & Baker, K. M. (1992) · Endocrinology · doi:10.1210/endo.130.6.1597161 · Cited by 154
Review: Angiotensin II type 1 receptor blockers: class effects versus molecular effects
Miura, S.-I., Karnik, S. S., & Saku, K. (2010) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320310370852 · Cited by 154
Role of CYP2C9 polymorphism in losartan oxidation.
Yaşar, Ü., Tybring, G., Hidestrand, M., Oscarson, M., Ingelman‐Sundberg, M., Dahl, M. L., & Eliasson, E. (2001) · PubMed · Cited by 151
Ojima, M., Igata, H., Tanaka, M., Sakamoto, H., Kuroita, T., Kohara, Y., Kubo, K., Fuse, H., Imura, Y., Kusumoto, K., et al. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176636 · Cited by 151
Rapid Identification of P-glycoprotein Substrates and Inhibitors
Chang, C. K., Bahadduri, P. M., Polli, J. E., Swaan, P. W., & Ekins, S. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012351 · Cited by 148
Aldosterone regulation of gene transcription leading to control of ion transport.
Horisberger, J., & Rossier, B. C. (1992) · Hypertension · doi:10.1161/01.hyp.19.3.221 · Cited by 145
Ohtawa, M., Takayama, F., Saitoh, K., YOSHINAGA, T., & Nakashima, M. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb05696.x · Cited by 144
Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
Ojima, M., Inada, Y., Shibouta, Y., Wada, T., Sanada, T., Kubo, K., & Nishikawa, K. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00837-0 · Cited by 143
Yamada, A., Maeda, K., Kamiyama, E., Sugiyama, D., Kondo, T., Shiroyanagi, Y., Nakazawa, H., Okano, T., Adachi, M., Schuetz, J. D., et al. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017459 · Cited by 143
Nishimura, Y., Ito, T., Hoe, K., & Saavedra, J. M. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02377-5 · Cited by 136
Molecular activation of PPARγ by angiotensin II type 1-receptor antagonists
Erbe, D. V., Gartrell, K., Zhang, Y., Suri, V., Kirincich, S. J., Will, S., Perreault, M., Wang, S., & Tobin, J. F. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2006.05.002 · Cited by 135
Telmisartan prevented cognitive decline partly due to PPAR-γ activation
Mogi, M., Li, J., Tsukuda, K., Iwanami, J., Min, L., Sakata, A., Fujita, T., Iwai, M., & Horiuchi, M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.032 · Cited by 134
Li, Z., Bains, J. S., & Ferguson, A. V. (1993) · Brain Research Bulletin · doi:10.1016/0361-9230(93)90036-b · Cited by 133
Waldmeier, F., Flesch, G., ̈ller, P. M., WINKLER, T., KRIEMLER, H. ‐., Bühlmayer, P., & Marc De Gasparo, B. (1997) · Xenobiotica · doi:10.1080/004982597240767 · Cited by 133
Washida, K., Ihara, M., Nishio, K., Fujita, Y., Maki, T., Yamada, M., Takahashi, J., Wu, X., Kihara, T., Ito, H., et al. (2010) · Stroke · doi:10.1161/strokeaha.110.583948 · Cited by 131
Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP 753.
Wong, P. C., Price, W. A., Chiu, A. T., et al. (1990) · Hypertension · doi:10.1161/01.hyp.15.6.823 · Cited by 130
Molecular Mechanism Underlying Inverse Agonist of Angiotensin II Type 1 Receptor
Miura, S.-I., Fujino, M., Hanzawa, H., Kiya, Y., Imaizumi, S., Matsuo, Y., Tomita, S., Uehara, Y., Karnik, S. S., Yanagisawa, H., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602144200 · Cited by 128
Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles
Kubo, K., Inada, Y., Kohara, Y., et al. (1993) · Journal of Medicinal Chemistry · doi:10.1021/jm00064a011 · Cited by 127
Angiotensin II Type 1 Receptor–Mediated Inflammation Is Required for Choroidal Neovascularization
Nagai, N., Oike, Y., Izumi‐Nagai, K., Urano, T., Kubota, Y., Noda, K., Ozawa, Y., Inoue, M., Tsubota, K., Suda, T., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000240050.15321.fe · Cited by 122
Binding of valsartan to mammalian angiotensin AT1 receptors
de Gasparo, M., & Whitebread, S. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00085-p · Cited by 121
Cianchetti, S., Fiorentino, A. D., Colognato, R., Stefano, R. D., Franzoni, F., & Pedrinelli, R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.09.013 · Cited by 119
Ohlstein, E. H., Brooks, D. P., Feuerstein, G., & Ruffolo, R. R., Jr. (2008) · Pharmacology · doi:10.1159/000139534 · Cited by 117
Guo, L., & Tabrizchi, R. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.10.009 · Cited by 117
Angiotensin II AT1 Receptor Antagonists. Clinical Implications of Active Metabolites
Schmidt, B., & Schieffer, B. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204237 · Cited by 114
Pharmacokinetics of CS‐866, a New Angiotensin II Receptor Blocker, in Healthy Subjects
Schwocho, L. R., & Masonson, H. N. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010393 · Cited by 114
Imayama, I., Ichiki, T., Inanaga, K., OHTSUBO, H., FUKUYAMA, K., ONO, H., Hashiguchi, Y., & Sunagawa, K. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.07.014 · Cited by 114
Čulman, J., Blume, A., Gohlke, P., & Unger, T. (2002) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001442 · Cited by 114
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174
KAUKONEN, K. ‐., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050405 · Cited by 111
He, H., Yang, D., Ma, L., Luo, Z., Ma, S., Feng, X., Cao, T., Yan, Z., Liu, D., Tepel, M., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.143958 · Cited by 110
Olmesartan Medoxomil: A Review of its Use in the Management of Hypertension
Scott, L. J., & McCormack, P. L. (2008) · Drugs · doi:10.2165/00003495-200868090-00005 · Cited by 109
Yoshida, T., Yamagishi, S., Nakamura, K., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0437-7 · Cited by 108
Pelisch, N., Hosomi, N., Ueno, M., Nakano, D., Hitomi, H., Mogi, M., Shimada, K., Kobori, H., Horiuchi, M., Sakamoto, H., et al. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.241 · Cited by 108
Distribution of angiotensin II receptor subtypes in rat brain nuclei
Obermüller, N., Unger, T., Čulman, J., Gohlke, P., de Gasparo, M., & Bottari, S. P. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90420-x · Cited by 105
Watanabe, T., Kusuhara, H., Watanabe, T., Debori, Y., Maeda, K., Kondo, T., Nakayama, H., Horita, S., Ogilvie, B. W., Parkinson, A., et al. (2011) · Drug Metabolism And Disposition · doi:10.1124/dmd.110.036129 · Cited by 105
Tolbutamide, Flurbiprofen, and Losartan as Probes of CYP2C9 Activity in Humans
Lee, C. R., Pieper, J. A., Hinderliter, A. L., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270002239710 · Cited by 103
Molecular Analysis of the Structure and Function of the Angiotensin II Type 1 Receptor
Miura, S.-I., Saku, K., & Karnik, S. S. (2003) · Hypertension Research · doi:10.1291/hypres.26.937 · Cited by 103
Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats
Groth, W., Blume, A., Gohlke, P., Unger, T., & Čulman, J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00028 · Cited by 103
Min, L., Mogi, M., Shudou, M., Jing, F., Tsukuda, K., Ohshima, K., Iwanami, J., & Horiuchi, M. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.192401 · Cited by 103
Iwanaga, T., Sato, M., Maeda, T., Ogihara, T., & Tamai, I. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.112755 · Cited by 103
Fujimoto, M., Masuzaki, H., Tanaka, T., Yasue, S., Tomita, T., Okazawa, K., Fujikura, J., Chusho, H., Ebihara, K., Hayashi, T., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.09.027 · Cited by 100
Nakagomi, R., Nakai, D., Kawai, K., Yoshigae, Y., Tokui, T., Abe, T., & Ikeda, T. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008888 · Cited by 100
Čulman, J., von Heyer, C., Piepenburg, B., Rascher, W., & Unger, T. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00983-2 · Cited by 99
Kobayashi, N., Ohno, T., Yoshida, K., Fukushima, H., Mamada, Y., Nomura, M., Hirata, H., Machida, Y., Shinoda, M., Suzuki, N., et al. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.27 · Cited by 98
Angiotensin II Receptor Blockade in Normotensive Subjects
Mazzolai, L., Maillard, M. P., Rossat, J., Nussberger, J., Brunner, H. R., & Burnier, M. (1999) · Hypertension · doi:10.1161/01.hyp.33.3.850 · Cited by 96
Self-citationPharmacokinetics of valsartan in patients with liver disease
Brookman, L. J., Rolan, P. E., BENJAMIN, I. S., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90029-1 · Cited by 94
Angiotensin II receptor subtypes in cultured rat renal mesangial cells
Ernsberger, P. R., Zhou, J., Damon, T. H., & Douglas, J. G. (1992) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1992.263.3.f411 · Cited by 94
Characterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy Volunteers
Delacrétaz, E., Nussberger, J., Biollaz, J., Waeber, B., & Brunner, H. R. (1995) · Hypertension · doi:10.1161/01.hyp.25.1.14 · Cited by 93
Self-citationSato, M., Iwanaga, T., Mamada, H., Ogihara, T., Yabuuchi, H., Maeda, T., & Tamai, I. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9401-6 · Cited by 91
Mire, D. E., Silfani, T. N., & Pugsley, M. K. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000180902.78230.fd · Cited by 90
Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase
MaassenVanDenBrink, A. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00249-7 · Cited by 90
Janke, J., Schupp, M., Engeli, S., Gorzelniak, K., Boschmann, M., Sauma, L., Nyström, F. H., Jordan, J., Luft, F. C., & Sharma, A. M. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000242405.68461.84 · Cited by 89
Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers*
Kazierad, D. J., Martin, D. E., Blum, R. A., Tenero, D. M., Ilson, B. E., Boike, S. C., Etheredge, R. C., & Jorkasky, D. K. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90120-x · Cited by 89
Comparative angiotensin II receptor blockade in healthy volunteers: The importance of dosing
Maillard, M. P., Wuerzner, G., Nussberger, J., et al. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121425 · Cited by 88
Aguilera, G. (1992) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(92)90101-b · Cited by 86
Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties
Deppe, S., Böger, R. H., Weiß, J., & Benndorf, R. A. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.494597 · Cited by 84
Antihypertensive Treatments, Cognitive Decline, and Dementia
Duron, E., & Hanon, O. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091552 · Cited by 83
Ishiguro, N., Maeda, K., Saito, A., Kishimoto, W., Matsushima, S., Ebner, T., Roth, W., Igarashi, T., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018903 · Cited by 81
Poggioli, J., Lázár, G., Houillier, P., Gardin, J. P., Achard, J. M., & Paillard, M. (1992) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1992.263.4.c750 · Cited by 80
Clemenz, M., Frost, N., Schupp, M., Caron, S., Foryst‐Ludwig, A., Böhm, C., Hartge, M., Gust, R., Staels, B., Unger, T., et al. (2008) · Diabetes · doi:10.2337/db07-0839 · Cited by 79
Le, M. T., Pugsley, M. K., Vauquelin, G., & Liefde, I. V. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707323 · Cited by 79
Abe, K., Bridges, A. S., Yue, W., & Brouwer, K. L. R. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.138073 · Cited by 78
Access of peripherally administered DuP 753 to rat brain angiotensin II receptors
Song, K., Zhuo, J. L., & Mendelsohn, F. A. O. (1991) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1991.tb12503.x · Cited by 77
Aranda, P. J., Segura, J., Ruilope, L. M., Aranda, F. J., Frutos, M. Á., López, V., & de Novales, E. L. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.034 · Cited by 77
Wong, T. P., Debnam, E. S., & Leung, P. S. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2007.138578 · Cited by 75
Characterization and distribution of angiotensin II receptor subtypes in the mouse brain
Häuser, W., Jöhren, O., & Saavedra, J. M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00134-4 · Cited by 75
YChristen, BWaeber, JNussberger, et al. (1991) · Circulation · Cited by 75
Trachtman, H., Hainer, J. W., Sugg, J. E., Teng, R., Sorof, J. M., Radcliffe, J., & Candesartan in Children with Hypertension (CINCH) Investigators (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00022.x · Cited by 74
Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects
Müller, P., Cohen, T., de Gasparo, M., Sioufi, A., Bacine-Poon, A., & HOWALD, H. (1994) · European Journal of Clinical Pharmacology · doi:10.1007/bf02570503 · Cited by 74
Effect of Telmisartan on Nitric Oxide–Asymmetrical Dimethylarginine System
Scalera, F., Martens‐Lobenhoffer, J., Bukowska, A., Lendeckel, U., Täger, M., & Bode‐Böger, S. M. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.104570 · Cited by 73
Schaefer, F. S., Walle, J. V., Zurowska, A. M., Gimpel, C., Hoeck, K. V., Drożdż, D., Montini, G., Bagdasorova, I. V., Sorof, J. M., Sugg, J. E., et al. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328336b86b · Cited by 72
Hosomi, N., Nishiyama, A., Ban, C. R., Naya, T., Takahashi, T., Kohno, M., & Koziol, J. A. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.054 · Cited by 72
Pharmacokinetic interaction study between quercetin and valsartan in rats andin vitromodels
Challa, V. R., Pingili, R. B., Challa, S. R., et al. (2012) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2012.693502 · Cited by 72
Pharmacokinetics and Pharmacodynamics of Irbesartan in Healthy Subjects
Marino, M. R., Langenbacher, K. M., Ford, N. F., et al. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04422.x · Cited by 72
Inada, Y., Wada, T., Shibouta, Y., et al. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38647-7 · Cited by 72
Yin, T., Maekawa, K., Kamide, K., Saito, Y., Hanada, H., Miyashita, K., Kokubo, Y., Akaiwa, Y., Otsubo, R., Nagatsuka, K., et al. (2008) · Hypertension Research · doi:10.1291/hypres.31.1549 · Cited by 69
Honda, A., Matsuura, K., Fukushima, N., Tsurumi, Y., Kasanuki, H., & Hagiwara, N. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.036 · Cited by 69
Role of Cytochrome P-4502C9 in Irbesartan Oxidation by Human Liver Microsomes
Bourrié, M., Meunier, V., Berger, Y., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15292-0 · Cited by 69
Biotransformation of irbesartan in man.
Chando, T. J., Everett, D. W., KAHLE, A. D., Starrett, A. M., Vachharajani, N. N., Shyu, W. C., Kripalani, K. J., & Barbhaiya, R. H. (1998) · PubMed · Cited by 69
Fujita, K., Yoneda, M., Wada, K., Mawatari, H., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., Maeyama, S., Saito, S., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9741-4 · Cited by 68
Bui, J. D., Kimura, B., & Phillips, M. I. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90593-s · Cited by 67
Fukuda, H., Ohashi, R., Tsuda-Tsukimoto, M., & Tamai, I. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019026 · Cited by 67
Pang, T., Benický, J., Wang, J., Orečná, M., Sánchez-Lemus, E., & Saavedra, J. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834dde5f · Cited by 66
Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker
Kajiya, T., Ho, C. I., Wang, J., Vilardi, R. F., & Kurtz, T. W. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834c46fd · Cited by 66
Montón, M., Jiménez, A., Núñez, A., et al. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200006000-00012 · Cited by 66
Structural basis for telmisartan-mediated partial activation of PPAR gamma
Amano, Y., Yamaguchi, T., Ohno, K., Niimi, T., Orita, M., Sakashita, H., & Takeuchi, M. (2012) · Hypertension Research · doi:10.1038/hr.2012.17 · Cited by 65
Blessing, E., Preusch, M. R., Kranzhöfer, R., Kinscherf, R., Marx, N., Rosenfeld, M. E., Isermann, B., Weber, C. M., Kreuzer, J., Gräfe, J., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.10.037 · Cited by 65
Ishizuka, T., Fujimori, I., Kato, M., Noji-Sakikawa, C., Saito, M., Yoshigae, Y., Kubota, K., Kurihara, A., Izumi, T., Ikeda, T., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072629 · Cited by 63
Saab, P. G., Llabre, M. M., Ma, M., DiLillo, V. G., McCalla, J. R., Fernander, A., Copen, R., Gellman, M. D., & Schneiderman, N. (2001) · Journal of Hypertension · doi:10.1097/00004872-200101000-00003 · Cited by 63
Molecular mechanisms of the antagonistic action between AT1 and AT2 receptors
Miura, S.-I., Matsuo, Y., Kiya, Y., Karnik, S. S., & Saku, K. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.11.008 · Cited by 63
Angiotensin inhibition stimulates PPARγ and the release of visfatin
Storka, A., Vojtassakova, E., Mueller, M., Kapiotis, S., Haider, D. G., Jungbauer, A., & Wolzt, M. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.02025.x · Cited by 62
Kasichayanula, S., Chang, M., Liu, X., Shyu, W.-C., Griffen, S. C., LaCreta, F. P., & Boulton, D. W. (2012) · Advances in Therapy · doi:10.1007/s12325-011-0098-x · Cited by 62
Telmisartan Enhances Cholesterol Efflux from THP-1 Macrophages by Activating PPARγ
Nakaya, K., Ayaori, M., Hisada, T., Sawada, S., Tanaka, N., Iwamoto, N., Ogura, M., Yakushiji, E., Kusuhara, M., Nakamura, H., et al. (2007) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14.133 · Cited by 62
Yamada, A., Maeda, K., Ishiguro, N., Tsuda, Y., Igarashi, T., Ebner, T., Roth, W., Ikushiro, S., & Sugiyama, Y. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283482502 · Cited by 61
Miura, S.-I., Okabe, A., Matsuo, Y., Karnik, S. S., & Saku, K. (2012) · Hypertension Research · doi:10.1038/hr.2012.147 · Cited by 61
Functional Selectivity in Adrenergic and Angiotensin Signaling Systems
Patel, C. B., Noor, N., & Rockman, H. A. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.067066 · Cited by 60
Han, Y., Guo, D., Chen, Y., et al. (2009) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0624-9 · Cited by 59
The pharmacokinetics of losartan in renal insufficiency
Ska, D. A., Lo, M., Shaw, W. C., Keane, W. F., Gehr, T. W. B., Halstenson, C. E., Lipschutz, K. H., Furtek, C. I., Ritter, M. A., & Shahinfar, S. (1995) · Journal of Hypertension · doi:10.1097/00004872-199507001-00007 · Cited by 57
Liu, E. C., Hedberg, A., Goldenberg, H. J., Harris, D. N., & Webb, M. L. (1992) · Prostaglandins · doi:10.1016/0090-6980(92)90070-a · Cited by 56
Casimiro‐Garcia, A., Filzen, G. F., Flynn, D. A., Bigge, C. F., Chen, J., Davis, J. A., Dudley, D. A., Edmunds, J. J., Esmaeil, N., Geyer, A. G., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200409s · Cited by 55
Berellini, G., Cruciani, G., & Mannhold, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049024x · Cited by 55
The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis*
Sica, D. A., Marino, M. R., HAMMETT, J., Ferreira, I., Gehr, T. W. B., & Ford, N. F. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90080-1 · Cited by 55
Noda, A., Fushiki, H., Murakami, Y., Sasaki, H., Miyoshi, S., Kakuta, H., & Nishimura, S. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.06.012 · Cited by 54
Kusumoto, K., Igata, H., Ojima, M., Tsuboi, A., Imanishi, M., Yamaguchi, F., Sakamoto, H., Kuroita, T., Kawaguchi, N., Nishigaki, N., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.07.014 · Cited by 53
Edwards, R. M., Trizna, W., Stack, E. J., & Weinstock, J. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12239-8 · Cited by 53
Gleiter, C. H., Jägle, C., Gresser, U., & Mörike, K. (2004) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2004.tb00146.x · Cited by 53
Verheijen, I., Fierens, F. L. P., DeBacker, J. P., et al. (2000) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2000.tb00443.x · Cited by 52
Christ, D. D., Wong, P. C., Wong, Y. N., Hart, S. D., Quon, C. Y., & Lam, G. N. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38613-1 · Cited by 52
Tian, Q., Miyazaki, R., Ichiki, T., Imayama, I., Inanaga, K., Ohtsubo, H., Yano, K., Takeda, K., & Sunagawa, K. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.126656 · Cited by 52
Deguchi, T., Watanabe, N., Kurihara, A., Igeta, K., Ikenaga, H., Fusegawa, K., Suzuki, N., Murata, S., Hirouchi, M., Furuta, Y., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037457 · Cited by 52
Fujino, M., Miura, S., Kiya, Y., Tominaga, Y., Matsuo, Y., Karnik, S., & Saku, K. (2010) · Hypertension Research · doi:10.1038/hr.2010.135 · Cited by 51
Rong, X., Li, Y., Ebihara, K., Zhao, M., Naowaboot, J., Kusakabe, T., Kuwahara, K., Murray, M. T., & Nakao, K. (2010) · Diabetologia · doi:10.1007/s00125-010-1744-6 · Cited by 51
BELZ, G. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1053/cp.1999.v66.a101162 · Cited by 50
Matsumura, T., Kinoshita, H., Ishii, N., Fukuda, K., Motoshima, H., Senokuchi, T., Taketa, K., Kawasaki, S., Nishimaki‐Mogami, T., Kawada, T., et al. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.222067 · Cited by 50
Shimizu, K., Takashima, T., Yamane, T., et al. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.01.008 · Cited by 50
Yamada, M., Kushibiki, M., Osanai, T., Tomita, H., & Okumura, K. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn064 · Cited by 50
Vachharajani, N. N., Shyu, W. C., Chando, T. J., et al. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04809.x · Cited by 49
Kusunoki, H., Taniyama, Y., Azuma, J., Iekushi, K., Sanada, F., Otsu, R., Iwabayashi, M., Okayama, K., Rakugi, H., & Morishita, R. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.176263 · Cited by 49
Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?
Ernsberger, P. R., & Koletsky, R. J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.11.008 · Cited by 47
Kappert, K., Tsuprykov, O., Kaufmann, J., Fritzsche, J., Ott, I., Goebel, M., Bähr, I. N., Häßle, P.-L., Gust, R., Fleck, E., et al. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.132886 · Cited by 47
Herbert, J., Delisée, C., Dol, F., et al. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90394-8 · Cited by 46
Leenen, F. H. H., & Yuan, B. (2001) · Hypertension · doi:10.1161/01.hyp.37.3.981 · Cited by 46
Kishi, T., Hirooka, Y., & Sunagawa, K. (2012) · Hypertension Research · doi:10.1038/hr.2012.63 · Cited by 45
Yamagishi, S., Matsui, T., Nakamura, K., Takeuchi, M., & Inoue, H. (2008) · Protein and Peptide Letters · doi:10.2174/092986608785203746 · Cited by 44
Faure, S., Oudart, N., Javellaud, J., Fournier, A. E., Warnock, D. G., & Achard, J. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249704.34607.4c · Cited by 44
Inhibitory Effect of Telmisartan on the Blood Pressure Response to Angiotensin II Challenge
Stangier, J., Su, C. P. F., van Heiningen, P. N. M., Meinicke, T. W., van Lier, J. J., de Bruin, H., Tamminga, W. J., & Jonkman, J. H. G. (2001) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200111000-00004 · Cited by 44
Balt, J. C., Mathy, M. J., Pfaffendorf, M., & van Zwieten, P. A. (2001) · Journal of Hypertension · doi:10.1097/00004872-200103000-00015 · Cited by 43
Shetty, S. S., & DelGrande, D. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39054-8 · Cited by 43
Li, J., Zhu, X., Cao, Y., & Shi, R. (2009) · Journal of Molecular Modeling · doi:10.1007/s00894-009-0612-0 · Cited by 42
He, Y., Ligueros‐Saylan, M., Sunkara, G., Sabo, R., Zhao, C. W., Wang, Y., Campestrini, J., Pommier, F., Dole, K., Marion, A. S., et al. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007307880 · Cited by 42
Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats
Zhao, M., Li, Y., Wang, J., Ebihara, K., Rong, X., Hosoda, K., Tomita, T., & Nakao, K. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01471.x · Cited by 42
Ferrington, L., Miners, J. S., Palmer, L. E., Bond, S. M., Povey, J. E., Kelly, P. A., Love, S., Horsburgh, K. J., & Kehoe, P. G. (2011) · PubMed Central · Cited by 41
Ikejima, H., Imanishi, T., Tsujioka, H., Kuroi, A., Kobayashi, K., Shiomi, M., Muragaki, Y., Mochizuki, S., Goto, M., Yoshida, K., et al. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f52c36 · Cited by 40
Ohno, K., Amano, Y., Kakuta, H., Niimi, T., Takakura, S., Orita, M., Miyata, K., Sakashita, H., Takeuchi, M., Komuro, I., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.11.139 · Cited by 40
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism
Suwannakul, S., Ieiri, I., Kimura, M., Kawabata, K., Kusuhara, H., Hirota, T., Irie, S., Sugiyama, Y., & Higuchi, S. (2008) · Journal of Human Genetics · doi:10.1007/s10038-008-0324-9 · Cited by 39
The clinical pharmacology of losartan in Japanese subjects and patients.
Nakashima, M., & Umemura, K. (1996) · PubMed · Cited by 39
Yong, C., Dias, V. C., & Stangier, J. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001203 · Cited by 37
Polidori, C., Ciccocioppo, R., Nisato, D., Cazaubon, C., & Massi, M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00329-x · Cited by 37
Toyama, K., Nakamura, T., Kataoka, K., Yasuda, O., Fukuda, M., Tokutomi, Y., Dong, Y., Ogawa, H., & Kim‐Mitsuyama, S. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.012 · Cited by 37
Nakano, A., Hattori, Y., Aoki, C., Jojima, T., & Kasai, K. (2009) · Hypertension Research · doi:10.1038/hr.2009.95 · Cited by 37
Yamamoto, K. I., Ohishi, M., Ho, C. I., Kurtz, T. W., & Rakugi, H. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.138750 · Cited by 37
Pharmacogenomics of G Protein-Coupled Receptor Ligands in Cardiovascular Medicine
Rosskopf, D., & Michel, M. C. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000612 · Cited by 37
Self-citationZanchi, A., Dulloo, A. G., Perregaux, C., Montani, J., & Burnier, M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2007 · Cited by 37
Perrier, L., Bourrié, M., Marti, E., Tronquet, C., Massé, D., Berger, Y., Magdalou, J., & Fabre, G. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22844-0 · Cited by 37
Goyal, S. N., Arora, S., Bhatt, T. K., Das, P., Sharma, A. K., Kumari, S., & Arya, D. S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.03.030 · Cited by 36
Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells
Steinmetz, M., Brouwers, C., Nickenig, G., & Waßmann, S. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00829.x · Cited by 36
Cited by
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Singh, K. D., & Karnik, S. S. (2020) · GPCRs · doi:10.1016/b978-0-12-816228-6.00020-9 · Cited by 704
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Metadata
- Authors
- Michel, M. C., Foster, C., Brunner, H. R., & Liu, L.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 65
- Issue
- 2
- Pages
- 809-848
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2097957153
- Cited by
- 301
- References
- 268
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.